David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ dollar's wings clipped, RBNZ tipped to go 50bps
Economy

NZ dollar's wings clipped, RBNZ tipped to go 50bps

The kiwi is sliding, but it is more about the greenback than the RBNZ. 

NZ market rises on potential for more Chinese stimulus
Markets Market Close

NZ market rises on potential for more Chinese stimulus

Overnight US bond yields were down.

Graham Skellern 04 Oct 2024
Blackpearl seeks $10m to help win higher-value customers
Markets

Blackpearl seeks $10m to help win higher-value customers

The NZX-listed company’s customers are primarily US-based.

Ben Moore 04 Oct 2024